2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-126109
    (±)-8-Prenylnaringenin 68682-02-0 99.97%
    (±)-8-Prenylnaringenin, a natural prenylated flavonoid, is a potent phytoestrogen. (±)-8-Prenylnaringenin is an orally active selective estrogen receptor modulator (SERM) (Estrogen Receptor/ERR) that inhibits ERα and ERβ with IC50s of 57 nM and 68 nM, respectively. (±)-8-Prenylnaringenin has anticancer effects, and can be used for osteoporosis research.
    (±)-8-Prenylnaringenin
  • HY-126488
    H-Ser-His-OH 67726-09-4 99.80%
    H-Ser-His-OH is a short peptide with hydrolysis cleavage activity, an endogenous metabolite.
    H-Ser-His-OH
  • HY-128417
    alpha-D-glucose 492-62-6 98.0%
    \alpha-D-glucose is a monosaccharide that has a more significant insulin stimulating effect than beta-D-glucose.
    alpha-D-glucose
  • HY-128872
    Etrinabdione 1818428-24-8 99.16%
    Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity.
    Etrinabdione
  • HY-129683
    AM3102 213182-22-0 98.0%
    AM3102 is an oleoylethanolamide (OEA) analog. AM3102 is an endogenous high-affinity PPAR-alpha agonist. AM3102 resists enzymatic hydrolysis, activates PPAR-alpha with high potency in vitro, and persistently reduces feeding when administered in vivo either parenterally or orally.
    AM3102
  • HY-131488
    8-Debenzoylpaeoniflorin 23532-11-8 99.81%
    8-Debenzoylpaeoniflorin, a monoterpene glycoside, is a natural product that could be isolated from the dried root of Paeonia lactiflora Pall. 8-Debenzoylpaeoniflorin has antihyperglycemic activity.
    8-Debenzoylpaeoniflorin
  • HY-13443B
    Exendin-4-Lys-azide TFA 99.84%
    Exendin-4-Lys-azide TFA (Compound Ex40) is an azide derivative of Exendin-4-Lys-azide, Exendin-4, which can be used for coupling/click chemistry.
    Exendin-4-Lys-azide TFA
  • HY-136066
    Tauro-ω-muricholic acid sodium 2456348-84-6
    Tauro-ω-muricholic acid sodium (TωMCA sodium) is a bile acid released by the liver and an analog of tauro-α-muricholic acid. Tauro-ω-muricholic acid sodium is investigated as a potential marker in plasma for early-onset neonatal sepsis (EOS) and cholestasis studies
    Tauro-ω-muricholic acid sodium
  • HY-136939
    CFTR corrector 6 2226970-01-8 98.15%
    CFTR corrector 6 is a potent potentiator of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). CFTR corrector 6 has the potential for cystic fibrosis (CF) and other CFTR associated disorders research.
    CFTR corrector 6
  • HY-139058
    23-epi-26-Deoxyactein 501938-01-8 98.65%
    23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.
    23-epi-26-Deoxyactein
  • HY-139094
    A6770 1331754-16-5 ≥99.0%
    A6770 is an orally active, potent sphingosine 1-phosphate (S1P) lyase (S1PL) inhibitor. A6770 is phosphorylated and the phosphorylated form directly inhibits S1P lyased.A6770, a potential key metabolite of THI, induces a [3H]dhS1P increase.
    A6770
  • HY-139313
    NHE3-IN-2 92434-13-4 98.65%
    NHE3-IN-2 is a Na+/H+ exchanger-3 (NHE3) inhibitor ( patent WO2001079186A1, example 6-Chlor-4-phenyl-2-chinazolinyl-guanidin).
    NHE3-IN-2
  • HY-139725
    CDK5-IN-1 2639540-19-3 98.47%
    CDK5-IN-1 is a potent CDK5 inhibitor with an IC50 less than 10 nM. CDK5-IN-1 is greater than 100-fold more active against CDK5 than CDK2. CDK5-IN-1 is used for kidney diseases research.
    CDK5-IN-1
  • HY-142059
    PDE5-IN-4 224788-36-7 99.60%
    PDE5-IN-4 is a phosphodiesterase 5 inhibitor. PDE5-IN-4 can be used for the research of acute myocardial infarction and damage caused by reperfusion, gastrointestinal diseases, damage caused by diabetes, and liver failure.
    PDE5-IN-4
  • HY-142693
    Angiogenesis agent 1 2765218-28-6 99.39%
    Angiogenesis agent 1 (compound C-31) is a salidroside-derivated glycoside analogue. Angiogenesis agent 1 is an activator of the HIF-1α pathway. Angiogenesis agent 1 has the potential for the research of diabetic hind limb ischemia.
    Angiogenesis agent 1
  • HY-143444
    JAK-IN-20 1654776-91-6 99.63%
    JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC50s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo.
    JAK-IN-20
  • HY-145150
    TRPC5-IN-1 2265215-18-5 98.97%
    TRPC5-IN-1 (Compound 6j) is a selective TRPC5 inhibitor with 50.5 % Inhibition for TRPC5 at 3 μM. TRPC5-IN-1 can be used for the research of chronic kidney disease (CKD).
    TRPC5-IN-1
  • HY-146453
    TGR5 Receptor Agonist 3 2643391-08-4
    TGR5 Receptor Agonist 3 (Compound 19) is a soft-agent G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonist with reduced gallbladder-filling effects (favorable gallbladder safety), with EC50s of 16.4 and 209 nM for hTGR5 and mTGR5, respectively.
    TGR5 Receptor Agonist 3
  • HY-148208
    S-(p-Nitrobenzyl)glutathione 6803-19-6 98.99%
    S-(p-Nitrobenzyl)glutathione is a competitive glutathionase inhibitor. S-(p-Nitrobenzyl)glutathione is converted to the corresponding cysteine derivatives by rat kidney microsomes. S-(p-Nitrobenzyl)glutathione can be used for the research of metabolic breakdown of glutathione by the glutathionase system.
    S-(p-Nitrobenzyl)glutathione
  • HY-148304
    VU6036720 3026597-12-3 99.89%
    VU6036720 is a potent and specific in vitro inhibitor of Kir4.1/5.1. VU6036720 can inhibit Kir4.1/5.1 channels with an IC50 value of 0.24 μM. VU6036720 can be used for the research of brain and kidney.
    VU6036720
Cat. No. Product Name / Synonyms Application Reactivity